Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FTC blockage of Amgen's US$28 BLN takeover of Horizon

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 01, 2023 10:35am

149 Views

Post# 35615867

RE:FTC blockage of Amgen's US$28 BLN takeover of Horizon

September 01, 2023 - FTC clears Amgen's US$28 BLN takeover of Horizon.

After months of legal wrangling, Amgen is free to go forward with its $27.8 billion buyout of Horizon Therapeutics.

With Amgen ultimately cleared to buy Horizon, the industry will likely celebrate the result. This, in turn, could prompt pharma's dealmakers to give large buyouts more consideration.

Amgen and Horizon now expect their deal to close “early” in the fourth quarter.

https://www.fiercepharma.com/pharma/amgens-28b-horizon-buyout-cleared-takeoff-after-ftc-states-settle

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages